期刊文献+

盐酸伊伐布雷定有关物质的合成 被引量:1

Synthesis of the Related Substances of Ivabradine Hydrochloride
原文传递
导出
摘要 为有效控制盐酸伊伐布雷定的质量,基于其合成工艺,制备了5种有关物质:7,8-二甲氧基-3-丙基-1,3-二氢-2H-苯并[d]氮?-2-酮(有关物质A)、3-烯丙基-7,8-二甲氧基-1,3-二氢-2H-苯并[d]氮?-2-酮(有关物质B)、3,3’-(丙烷-1,3-二基)双(7,8-二甲氧基-1,3-二氢-2H-苯并[d]氮?-2-酮)(有关物质C)、(S)-[2-[2-[[3-[[[3,4-二甲氧基二环[4.2.0]辛-1(6),2,4-三烯-7-基]甲基](甲基)氨基]丙基]氨基]乙基]-4,5-二甲氧基苯基]乙酸(有关物质D)及3-(7,8-二甲氧基-2-氧代-1,2,4,5-四氢-3H-苯并[d]氮?-3-基)-N-[[(S)-3,4-二甲氧基双环[4.2.0]八-1(6),2,4-三烯-7-基]甲基]-N-甲基丙烷-1-胺氧化物(有关物质E)。结构均经由MS和;H NMR确证,其中有关物质A和B未见文献报道。 In order to control the quality of ivabradine hydrochloride,five related substances were prepared:7,8-dimethoxy-3-propyl-1,3-dihydro-2H-benzo[d]azepin-2-one(related substance A),3-allyl-7,8-dimethoxy-1,3-dihydro-2H-benzo[d]azepin-2-one(related substance B),3,3’-(propane-1,3-diyl)bis(7,8-dimethoxy-1,3-dihydro-2H-benzo[d]-azepin-2-one)(related substance C),(S)-[2-[2-[[3-[[[3,4-dimethoxybicyclo[4.2.0]octa-1(6),2,4-trien-7-yl]methyl]-(methyl)amino]propyl]amino]ethyl]-4,5-dimethoxyphenyl]acetic acid(related substance D),3-(7,8-dimethoxy-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)-N-[[(S)-3,4-dimethoxybicyclo[4.2.0]octa-1(6),2,4-triene-7-yl]methyl]-N-methylpropan-1-amine oxide(related substance E).The structures were confirmed by MS and ~1H NMR.Among them,both related substance A and B have not found in literature.
作者 张振 王冠 仇永富 刘旭岩 李建其 ZHANG Zhen;WANG Guan;QIU Yongfu;LIU Xuyan;LI Jianqi(School of Chemistry and Chemical Engineering,Shanghai University of Engineering Science,Shanghai 201620;Shanghai Institute of Pharmaceutical Industry,China State Institute of Pharmaceutical Industry,Shanghai 201203)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2022年第4期481-485,共5页 Chinese Journal of Pharmaceuticals
关键词 盐酸伊伐布雷定 质量控制 有关物质 合成 ivabradine hydrochloride quality control related substance synthesis
  • 相关文献

参考文献3

二级参考文献40

  • 1刘燕平,黄昕明,王德才.7,8-二甲氧基-3-(3-碘丙基)-1,3-二氢-2H-3-苯并氮杂-2-酮的制备[J].华西药学杂志,2008,23(3):267-268. 被引量:1
  • 2Alberto Dominguez-Rodriguez,Gabriela Blanco-Palacios,Pedro Abreu-Gonzalez.Increased heart rate and atherosclerosis: Potential implications of ivabradine therapy[J].World Journal of Cardiology,2011,3(4):101-104. 被引量:14
  • 3Brown H, Difrancesco D. Voltage-clamp investigations of membrane currents underlying pace-maker activity in rabbit sino-atrial node[J]. J Physiol, 1980, 308(8): 331-351.
  • 4Manz M, Reuter M, Lauck G; et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction[J]. Cardiology, 2003, 100(2): 149-155.
  • 5Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise[J]. Am J Physiol Heart Cite Physiol, 2002, 282(7): H672-679.
  • 6Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the international verapamil-SR/trandolapril study (INVEST)[J]. Eur Heart J, 2008, 29(2): 1327-1334.
  • 7Siasos G, Tousoulis D, Athanasiou D, et al. Novel risk factors related to stable angina[J]. Curr Pharm Des, 2013, 19(2): 1550-1561.
  • 8Arrebola-Moreno A, Dungu J, Kaski JC. Treatment strategies for chronic stable angina[J]. Expert Opin Pharmacother, 2011, 12(3): 2833-2844.
  • 9Riccioni G Ivabradine: an intelligent drug for the treatment of ischemic heart disease[J]. Molecules, 2012, 17(2): 13592-13604.
  • 10Doesch AO, Mueller S, Erbel C, et al. Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograil recipients: a long-term follow-up study[J]. Drag Des Devel Ther, 2013, 7(1): 1323-1328.

共引文献40

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部